Table 5

Cost-benefit analyses of vaccination programs in the general population
First author [Reference] Bjerregaard [[28]] Pelletier [[29]] Elo [[31]] Berger [[30]]
Country Denmark Canada Finland Israel
Year 1991 1998 1979 1990
WB income group High High High High
Comparators 1. Vaccinate 15-month and 12-yr-olds 1. 1-dose child vaccination campaign 1. Vaccinate 13-yr-olds & post-partum women 1. Vaccinate children from 1 – 12 years
2. Vaccinate only 15-month-olds 2. 2-dose child vaccination campaign 2. Vaccinate 13-yr-olds & 1-yr-olds 2. Vaccinate only 12-yr-olds (routine)
3. 1-dose child vaccination 3. Vaccinate only 1-yr-olds over 20 years
4. 2-dose child vaccination
Perspective Societal* Societal* Societal* NR
Cost components measured OP visits; prescriptions; hospitalizations; vaccines OP visits; hospitalizations; laboratory tests; nursing home care; special education; indirect costs (lost productivity for illness, disability and premature death) Fetal loss; fetal damage; annual costs; long-term costs Vaccine; vaccination side effects; serology; OP visits; hospitalizations; hearing aids; mothers’ work loss;
Method of cost estimation Micro-costing Micro-costing; Lifetime earnings (for indirect costs) Top-down costing based on Delphi panel Micro-costing
Method of benefits estimation Averted costs Averted costs Averted costs Averted costs
Time period for costs and benefits 20 years Lifetime 30 years 13 years
Discounting (Rate) NR Yes (5%) Yes (6%) Yes (5 and 10%)
Results—Benefit-cost ratio 1. 3 1. 2.6 1. 10 1. 1.1
2. 2 2. 2.9 2. 3 2. 1.8
3. 3.6 3. 6
4. 4.3
Stated conclusion Vaccinating both age groups is preferable The benefits of a second dose outweigh the costs Vaccinating 13-yr-old girls and postpartum women was preferable Vaccinating infants and adolescent girls is preferable

*Not explicitly reported but inferred.

WB, World Bank; NR, Not Reported; NA, Not Applicable; OP, Out Patient; CDC, US Centers for Disease Control and Prevention; LCDC, Canada Laboratory Center for Disease Control.

Babigumira et al.

Babigumira et al. BMC Public Health 2013 13:406   doi:10.1186/1471-2458-13-406

Open Data